Effect of Distreptaza Distrept on the specific activity of fluconazole against Candida biofilms





biofilm, enzymes, Distreptaza Distrept, antifungal agents, Candida spp.


The ability of yeast-like fungi to form biofilms (structurally organized microbial communities) leads to chronicity of the inflammatory process and recurrent course of mycoses. Biofilms formed by the fungus Candida spp. are characterized by increased resistance to most antifungals and effectors of the immune system. Promising antibiotics are enzymes. Their specificity to the structural components of the biofilm can be used to prevent biofilm formation and destruction of the formed biofilm. The article presents the results of studying the sensitivity biofilms formed by Candida fungi to the action of the enzyme drug Distreptaza Distrept, as well as its effect on the specific antifungal activity of fluconazole.
Research objective: to evaluate the Distreptaza Distrept impact on the antifungal activity of fluconazole on biofilms of Candida spp.
Materials and methods. One-day cultures of C. albicans and C. glabrata were used in the experiments. To study the effect on biofilm formation Distreptaza Distrept, fluconazole solutions and microorganisms were applied simultaneously, when exposed to the formed biofilms for 24 h after application of the fungal inoculum. The experiments were carried out in accordance with conventional methods based on the sorption of gentian violet by biofilm structures with subsequent desorption of the dye in an organic solvent.
Results. Experiments have shown that Distreptaza Distrept disrupts the film formation of C. glabrata, the inhibition is 85.6%. The enzyme preparation affects the biofilms formed by yeast-like fungi, biomass of C. glabrata decreases by 43.6%. It was found that Distreptaza Distrept enhances the specific antibiotic action of fluconazole at the stage of film formation against C. albicans by 13.1%, C. glabrata by 70.4%. Biomass of the one-day biofilm formed by C. glabrata is reduced by 80.2% if there was an enzyme drug and fluconazole in the incubation medium.
Conclusion. Distreptaza Distrept has antibiotic biofilm activity, increases the specific antifungal effect of fluconazole on biofilms of Candida fungi. The data obtained indicate the feasibility of this drug in recurrent infections caused by yeast-like fungi, including diseases caused by azole-resistant strains of Candida spp.

Author Biographies

N.O. Vrynchanu, SI “Institute of Pharmacology and Toxicology of the NAMS of Ukraine”, Kyiv

MD, head of the Laboratory of Pharmacology of Antimicrobial Agents

N.I. Hrynchuk, SI “Institute of Pharmacology and Toxicology of the NAMS of Ukraine”, Kyiv

Junior researcher

V.V. Samsonova, SI “Institute of Pharmacology and Toxicology of the NAMS of Ukraine”, Kyiv

General practitioner


Karapetyan, T.E., Naskhletashvili, I.V., Tyutyunnik, V.L. Vulvovaginal candidiasis: a modern view of the problem. ”Russian Medical Journal. Mother and childe 1 (2011): 64–7.

Sukhanova, A.A., Savchenko, S.Y., Kolomiichenko, T.V. “Possibilities of correction of local immunity in women with recurrent vulvovaginal candidiasis.” Woman’s health 5 (2016): 120–5.

Vrynchanu, N.O. “Candidiasis. Problems and prospects of antifungal therapy (part I).” Farmakolohiia ta likarska toksykolohiia 6 (2016): 3–11.

Medvedev, M.V. “Vulvovaginal candidiasis: the evolution of therapeutic approaches.” Reproductive endocrinology 2 (2015): 29–32.

Rakhmatulina, M.R., Shatalova, A.Y. “Modern ideas about the microbiocenosis of the vaginal biotope and its disorders in women of reproductive age.” Vestnik dermatologii i venerologii 3 (2009): 38–42.

Yanab, J., Bassler, B.L. “Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms.” Cell Host Microbe 26.1 (2019): 15–21. DOI: 0.1016/j.chom.2019.06.002

Tatarchuk, T.F., Kosei, N.V., Zanko, O.V., Yusko, T.I. “Endometrial polyps: optimization of anti-inflammatory therapy.” Reproductive endocrinology 6.44 (2019): 8–14. DOI: 10.18370/2309-4117.2018.44.8-148.

Iñigo, М., Del Pozo, J.L. “Fungal biofilms: From bench to bedside.” Review Rev Esp Quimioter 31 Suppl 1 (2018): 35–8.

Wu, S., Wang, Y., Na, L., et al. “Tackling Fungal Resistance by Biofilm Inhibitors.” J Med Chem 60.6 (2017): 2193–211.

Bernard, C., Girardot, M., Imbert C. “Candida albicans interaction with Gram-positive bacteria within interkingdom biofilms.” J Mycol Med 30.1 (2020): 100909.

Lagree, K., Aaron, P.M. “Fungal Biofilms: Inside Out.” Microbiol Spectr 5.2 (2017).

Olson, M.L., Jayaraman, A., Kao, K.C. “Relative Abundances of Candida albicans and Candida glabrata in In Vitro Coculture Biofilms Impact Biofilm Structure and Formation.” Appl Environ Microbiol 84.8 (2018): e02769-17.

Terentyeva, N.A., Timchenko, N.F., Balabanova, L.A. “Influence of enzymes on the formation of bacterial biofilms.” Health. Medical ecology. Science 2 (2015): 86–93.

Hernandez-Bernal, F., Valenzuela-Silva, C.M., et al. “Recombinant streptokinase suppositories in the treatment of acute haemorrhoidal disease. Multicentre randomized doubleblind placebo-controlled trial (THERESA-2).” Colorectal Disease 15 (2013): 1423–8.

Hernandez-Bernal, F., Castellanos-Sierra, G., et al. “Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3).” World J Gastroenterol 20.6 (2014): 1594–1601.

Hernandez-Bernal, F., Castellanos-Sierra, G., et al. “Recombinant streptokinase vs hydrocortisone suppositories in acute hemorrhoids: A randomized controlled trial (THERESA-4).” World J Gastroenterol 21.23 (2015): 7305–12.

Zapotoczna, M., O’Neill, E., O'Gara, J.P. “Untangling the Diverse and Redundant Mechanisms

of Staphylococcus aureus Biofilm Formation / 3*.” PLOS Pathogens (2016). DOI: 10.1371/journal.ppat.1005671

Carothers, K.E., Liang, Z., Mayfield, J., et al. “The Streptococcal Protease SpeB Antagonizes the Biofilms of the Human Pathogen Staphylococcus aureus USA300 through Cleavage of the Staphylococcal SdrC Protein.” J Bacteriol 202.11 (2020). DOI: 10.1128/JB.00008-20

Hogan, S., O'Gara, J.P., O'Neill, E. “Novel treatment of Staphylococcus aureus device-related infections using fibrinolytic agents.” Antimicrobial agents and chemotherapy 62.2 (2018): e02008-17.

Kaiyu Zhang, Xin Li, Chen Yu, Yang Wang. “Promising Therapeutic Strategies Against Microbial Biofilm Challenges / 1,2.” Front Cell Infect Microbiol 10 (2020): 359. DOI: 10.3389/fcimb.2020.00359

Shakir, A., et al. “Removal of Biofilms from Tracheoesophageal Speech Valves Using a Novel Marine Microbial Deoxyribonuclease.” Otolaryngology-Head and Neck Surgery 147.3 (2012): 509–14. DOI: 10.1177/0194599812442867

Taylor, P.K., Yeung, A.T.Y., Hancock, R.E.W. “Antibiotic resistance in Pseudomonas aeruginosa biofilms: Towards thedevelopment of novel anti-biofilm therapies.” Journal of Biotechnology 191 (2014): 121–30.

Panariello, B.H., Klein, M.I., Alves, F., Pavarina, A.C. “DNase increases the efficacy of antimicrobial photodynamic therapy on Candida albicans biofilms.” Photodiagnosis Photodyn Ther 27 (2019):124–31.

Banu, S. F., Thamotharan, S., Gowrishankar, S., et al. “Marine bacterial DNase curtails virulence and disrupts biofilms of Candida albicans and non-albicans Candida species.” Biofouling 35.9 (2019): 975–85. DOI: 10.1080/08927014.2019.1680650

Al-Obaidi, H., Kowalczyk, R.M., Kalgudi, R., Zariwala, M.G. “Griseofulvin solvate solid dispersions with synergistic effect against fungal biofilms.” Colloids Surf B Biointerfaces 184 (2019):110540.

Taraszkiewicz, A., Fila, G., Grinholc, M., et al. “Innovative Strategies to Overcome Biofilm Resistance.” BioMed Research International Special Issue (2013). DOI: 10.1155/2013/150653

O'Toole, G.A. “Microtiter dish biofilm formation assay.” J Vis Exp 47 (2011): 2437. DOI: 10.3791/2437